Belluscura PLC
("Belluscura" or the "Company" or "Group")
Third US Distribution Agreement
LONDON, U.K. AND PLANO, TX, U.S. (13 July 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces the signing of its third distribution agreement and first agreement with a durable medical equipment ("DME") provider, for its X-PLO2R™ portable oxygen concentrator ("POC") portfolio. This is the next stage in establishing US-wide distribution coverage as part of the Group's commercialisation strategy.
The provider, a DME located in the upper Midwest US, has multiple stores in several states and an online store. The distributor issued its first purchase order with anticipated delivery of the X-PLO2R™ portable oxygen concentrator expected in less than ninety days.
As described in the Company's Admission Document, Belluscura's plan is to appoint distributors in the US to give US-wide coverage for the launch of the X-PLO2R™; and this is expected to occur in the second half of 2021 and into 2022.
About the X-PLO₂R™
The X-PLO₂R™ weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world's first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other US Food & Drug Administration ("FDA") cleared POC in its class. The X-PLO2R™ can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO₂R™ is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.
In March 2021 Belluscura received 510(k) clearance from the FDA for the X-PLO2R™, which will be launched commercially in Q3 2021. Additional products within the range will be launched within the next 12 months.
Robert Rauker, CEO of Belluscura plc, said: "Having the X-PLO2R™ portable oxygen concentrator available in stores for potential customers to hold and feel, we believe, will help drive sales of the units. We look forward to commercial launch which we anticipate to start in just a few months."
For further information please contact:
|
Belluscura plc |
|
|
Robert Rauker, Chief Executive Officer |
via Walbrook PR |
|
Anthony Dyer, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin |
|
|
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Nicholas Chambers |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
|
Paul McManus / Sam Allen |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach†in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
